This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pan, X.-S.
Right arrow Articles by Fisher, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pan, X.-S.
Right arrow Articles by Fisher, L. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 1998, p. 2810-2816, Vol. 42, No. 11
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

DNA Gyrase and Topoisomerase IV Are Dual Targets of Clinafloxacin Action in Streptococcus pneumoniae

Xiao-Su Pan and L. Mark Fisher*

Molecular Genetics Group, Department of Biochemistry, St. George's Hospital Medical School, University of London, London SW17 ORE, United Kingdom

Received 1 May 1998/Returned for modification 21 July 1998/Accepted 14 August 1998

We examined the response of Streptococcus pneumoniae 7785 to clinafloxacin, a novel C-8-substituted fluoroquinolone which is being developed as an antipneumococcal agent. Clinafloxacin was highly active against S. pneumoniae 7785 (MIC, 0.125 µg/ml), and neither gyrA nor parC quinolone resistance mutations alone had much effect on this activity. A combination of both mutations was needed to register resistance, suggesting that both gyrase and topoisomerase IV are clinafloxacin targets in vivo. The sparfloxacin and ciprofloxacin MICs for the parC-gyrA mutants were 16 to 32 and 32 to 64 µg/ml, respectively, but the clinafloxacin MIC was 1 µg/ml, i.e., within clinafloxacin levels achievable in human serum. S. pneumoniae 7785 mutants could be selected stepwise with clinafloxacin at a low frequency, yielding first-, second-, third-, and fourth-step mutants for which clinafloxacin MICs were 0.25, 1, 6, and 32 to 64 µg/ml, respectively. Thus, high-level resistance to clinafloxacin required four steps. Characterization of the quinolone resistance-determining regions of the gyrA, parC, gyrB, and parE genes by PCR, HinfI restriction fragment length polymorphism, and DNA sequence analysis revealed an invariant resistance pathway involving sequential mutations in gyrA or gyrB, in parC, in gyrA, and finally in parC or parE. No evidence was found for other resistance mechanisms. The gyrA mutations in first- and third-step mutants altered GyrA hot spots Ser-83 to Phe or Tyr (Escherichia coli coordinates) and Glu-87 to Gln or Lys; second- and fourth-step parC mutations changed equivalent hot spots Ser-79 to Phe or Tyr and Asp-83 to Ala. gyrB and parE changes produced novel alterations of GyrB Glu-474 to Lys and of Pro-454 to Ser in the ParE PLRGK motif. Difficulty in selecting first-step gyrase mutants (isolated with 0.125 [but not 0.25] µg of clinafloxacin per ml at a frequency of 5.0 × 10-10 to 8.5 × 10-10) accompanied by the small (twofold) MIC increase suggested only a modest drug preference for gyrase. Given the susceptibility of defined gyrA or parC mutants, the results suggested that clinafloxacin displays comparable if unequal targeting of gyrase and topoisomerase IV. Dual targeting and the intrinsic potency of clinafloxacin against S. pneumoniae and its first- and second-step mutants are desirable features in limiting the emergence of bacterial resistance.

* Corresponding author. Mailing address: Molecular Genetics Group, Department of Biochemistry, St. George's Hospital Medical School, University of London, Cranmer Terrace, London SW17 ORE, United Kingdom. Phone: 44 181 725 5782. Fax: 44 181 725 2992. E-mail: lfisher{at}sghms.ac.uk.

Antimicrobial Agents and Chemotherapy, November 1998, p. 2810-2816, Vol. 42, No. 11
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Pan, X.-S., Gould, K. A., Fisher, L. M. (2009). Probing the Differential Interactions of Quinazolinedione PD 0305970 and Quinolones with Gyrase and Topoisomerase IV. Antimicrob. Agents Chemother. 53: 3822-3831 [Abstract] [Full Text]  
  • Cambau, E., Matrat, S., Pan, X.-S., Roth Dit Bettoni, R., Corbel, C., Aubry, A., Lascols, C., Driot, J.-Y., Fisher, L. M. (2009). Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother 63: 443-450 [Abstract] [Full Text]  
  • German, N., Malik, M., Rosen, J. D., Drlica, K., Kerns, R. J. (2008). Use of Gyrase Resistance Mutants To Guide Selection of 8-Methoxy-Quinazoline-2,4-Diones. Antimicrob. Agents Chemother. 52: 3915-3921 [Abstract] [Full Text]  
  • Pan, X. S., Dias, M., Palumbo, M., Fisher, L. M. (2008). Clerocidin selectively modifies the gyrase-DNA gate to induce irreversible and reversible DNA damage. Nucleic Acids Res 36: 5516-5529 [Abstract] [Full Text]  
  • Richter, S. N., Giaretta, G., Comuzzi, V., Leo, E., Mitchenall, L. A., Fisher, L. M., Maxwell, A., Palumbo, M. (2007). Hot-spot consensus of fluoroquinolone-mediated DNA cleavage by Gram-negative and Gram-positive type II DNA topoisomerases. Nucleic Acids Res 35: 6075-6085 [Abstract] [Full Text]  
  • Escudero, J. A., San Millan, A., Catalan, A., de la Campa, A. G., Rivero, E., Lopez, G., Dominguez, L., Moreno, M. A., Gonzalez-Zorn, B. (2007). First Characterization of Fluoroquinolone Resistance in Streptococcus suis. Antimicrob. Agents Chemother. 51: 777-782 [Abstract] [Full Text]  
  • Grossman, T. H., Bartels, D. J., Mullin, S., Gross, C. H., Parsons, J. D., Liao, Y., Grillot, A.-L., Stamos, D., Olson, E. R., Charifson, P. S., Mani, N. (2007). Dual Targeting of GyrB and ParE by a Novel Aminobenzimidazole Class of Antibacterial Compounds. Antimicrob. Agents Chemother. 51: 657-666 [Abstract] [Full Text]  
  • Oyamada, Y., Ito, H., Inoue, M., Yamagishi, J.-i. (2006). Topoisomerase mutations and efflux are associated with fluoroquinolone resistance in Enterococcus faecalis.. J Med Microbiol 55: 1395-1401 [Abstract] [Full Text]  
  • Oyamada, Y., Ito, H., Fujimoto, K., Asada, R., Niga, T., Okamoto, R., Inoue, M., Yamagishi, J.-i. (2006). Combination of known and unknown mechanisms confers high-level resistance to fluoroquinolones in Enterococcus faecium. J Med Microbiol 55: 729-736 [Abstract] [Full Text]  
  • Richter, S. N., Leo, E., Giaretta, G., Gatto, B., Fisher, L. M., Palumbo, M. (2006). Clerocidin interacts with the cleavage complex of Streptococcus pneumoniae topoisomerase IV to induce selective irreversible DNA damage. Nucleic Acids Res 34: 1982-1991 [Abstract] [Full Text]  
  • Strahilevitz, J., Robicsek, A., Hooper, D. C. (2006). Role of the Extended {alpha}4 Domain of Staphylococcus aureus Gyrase A Protein in Determining Low Sensitivity to Quinolones. Antimicrob. Agents Chemother. 50: 600-606 [Abstract] [Full Text]  
  • Strahilevitz, J., Truong-Bolduc, Q. C., Hooper, D. C. (2005). DX-619, a Novel Des-Fluoro(6) Quinolone Manifesting Low Frequency of Selection of Resistant Staphylococcus aureus Mutants: Quinolone Resistance beyond Modification of Type II Topoisomerases. Antimicrob. Agents Chemother. 49: 5051-5057 [Abstract] [Full Text]  
  • Galbraith, K. M., Ng, A. C., Eggers, B. J., Kuchel, C. R., Eggers, C. H., Samuels, D. S. (2005). parC Mutations in Fluoroquinolone-Resistant Borrelia burgdorferi. Antimicrob. Agents Chemother. 49: 4354-4357 [Abstract] [Full Text]  
  • Lindgren, P. K., Marcusson, L. L., Sandvang, D., Frimodt-Moller, N., Hughes, D. (2005). Biological Cost of Single and Multiple Norfloxacin Resistance Mutations in Escherichia coli Implicated in Urinary Tract Infections. Antimicrob. Agents Chemother. 49: 2343-2351 [Abstract] [Full Text]  
  • Strahilevitz, J., Hooper, D. C. (2005). Dual Targeting of Topoisomerase IV and Gyrase To Reduce Mutant Selection: Direct Testing of the Paradigm by Using WCK-1734, a New Fluoroquinolone, and Ciprofloxacin. Antimicrob. Agents Chemother. 49: 1949-1956 [Abstract] [Full Text]  
  • Jimenez, M. R. M., Bellido, J. L. M., Garcia Rodriguez, J. A. (2005). Risk Factors Associated with Colonization by Pneumococci with Reduced Susceptibility to Fluoroquinolones in Adult Outpatients. J. Clin. Microbiol. 43: 1193-1197 [Abstract] [Full Text]  
  • Grohs, P., Podglajen, I., Gutmann, L. (2004). Activities of Different Fluoroquinolones against Bacillus anthracis Mutants Selected In Vitro and Harboring Topoisomerase Mutations. Antimicrob. Agents Chemother. 48: 3024-3027 [Abstract] [Full Text]  
  • Gould, K. A., Pan, X.-S., Kerns, R. J., Fisher, L. M. (2004). Ciprofloxacin Dimers Target Gyrase in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48: 2108-2115 [Abstract] [Full Text]  
  • Bellon, S., Parsons, J. D., Wei, Y., Hayakawa, K., Swenson, L. L., Charifson, P. S., Lippke, J. A., Aldape, R., Gross, C. H. (2004). Crystal Structures of Escherichia coli Topoisomerase IV ParE Subunit (24 and 43 Kilodaltons): a Single Residue Dictates Differences in Novobiocin Potency against Topoisomerase IV and DNA Gyrase. Antimicrob. Agents Chemother. 48: 1856-1864 [Abstract] [Full Text]  
  • Johnson, A. P., Sheppard, C. L., Harnett, S. J., Birtles, A., Harrison, T., Brenwald, N. P., Gill, M. J., Walker, R. A., Livermore, D. M., George, R. C. (2003). Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England. J Antimicrob Chemother 52: 953-960 [Abstract] [Full Text]  
  • Grohs, P., Houssaye, S., Aubert, A., Gutmann, L., Varon, E. (2003). In Vitro Activities of Garenoxacin (BMS-284756) against Streptococcus pneumoniae, Viridans Group Streptococci, and Enterococcus faecalis Compared to Those of Six Other Quinolones. Antimicrob. Agents Chemother. 47: 3542-3547 [Abstract] [Full Text]  
  • Sifaoui, F., Lamour, V., Varon, E., Moras, D., Gutmann, L. (2003). ATP-Bound Conformation of Topoisomerase IV: a Possible Target for Quinolones in Streptococcus pneumoniae. J. Bacteriol. 185: 6137-6146 [Abstract] [Full Text]  
  • Komp Lindgren, P., Karlsson, A., Hughes, D. (2003). Mutation Rate and Evolution of Fluoroquinolone Resistance in Escherichia coli Isolates from Patients with Urinary Tract Infections. Antimicrob. Agents Chemother. 47: 3222-3232 [Abstract] [Full Text]  
  • Nilius, A. M., Shen, L. L., Hensey-Rudloff, D., Almer, L. S., Beyer, J. M., Balli, D. J., Cai, Y., Flamm, R. K. (2003). In Vitro Antibacterial Potency and Spectrum of ABT-492, a New Fluoroquinolone. Antimicrob. Agents Chemother. 47: 3260-3269 [Abstract] [Full Text]  
  • Fisher, L. M., Gould, K. A., Pan, X.-S., Patel, S., Heaton, V. J. (2003). Analysis of dual active fluoroquinolones in Streptococcus pneumoniae. J Antimicrob Chemother 52: 312-313 [Full Text]  
  • Smith, H. J., Nichol, K. A., Hoban, D. J., Zhanel, G. G. (2003). Reply. J Antimicrob Chemother 52: 313-314 [Full Text]  
  • Price, L. B., Vogler, A., Pearson, T., Busch, J. D., Schupp, J. M., Keim, P. (2003). In Vitro Selection and Characterization of Bacillus anthracis Mutants with High-Level Resistance to Ciprofloxacin. Antimicrob. Agents Chemother. 47: 2362-2365 [Abstract] [Full Text]  
  • Drlica, K. (2003). The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52: 11-17 [Abstract] [Full Text]  
  • Bui, M.-H., Stone, G. G., Nilius, A. M., Almer, L., Flamm, R. K. (2003). PCR-Oligonucleotide Ligation Assay for Detection of Point Mutations Associated with Quinolone Resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47: 1456-1459 [Abstract] [Full Text]  
  • Fisher, L. M., Heaton, V. J. (2003). Dual activity of fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother 51: 463-464 [Full Text]  
  • Kishii, R., Takei, M., Fukuda, H., Hayashi, K., Hosaka, M. (2003). Contribution of the 8-Methoxy Group to the Activity of Gatifloxacin against Type II Topoisomerases of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47: 77-81 [Abstract] [Full Text]  
  • Ince, D., Zhang, X., Silver, L. C., Hooper, D. C. (2003). Topoisomerase Targeting with and Resistance to Gemifloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 274-282 [Abstract] [Full Text]  
  • Minnick, M. F., Wilson, Z. R., Smitherman, L. S., Samuels, D. S. (2003). gyrA Mutations in Ciprofloxacin-Resistant Bartonella bacilliformis Strains Obtained In Vitro. Antimicrob. Agents Chemother. 47: 383-386 [Abstract] [Full Text]  
  • Ince, D., Zhang, X., Silver, L. C., Hooper, D. C. (2002). Dual Targeting of DNA Gyrase and Topoisomerase IV: Target Interactions of Garenoxacin (BMS-284756, T-3811ME), a New Desfluoroquinolone. Antimicrob. Agents Chemother. 46: 3370-3380 [Abstract] [Full Text]  
  • Croisier, D., Chavanet, P., Lequeu, C., Ahanou, A., Nierlich, A., Neuwirth, C., Piroth, L., Duong, M., Buisson, M., Portier, H. (2002). Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother 50: 349-360 [Abstract] [Full Text]  
  • Pan, X.-S., Hamlyn, P. J., Talens-Visconti, R., Alovero, F. L., Manzo, R. H., Fisher, L. M. (2002). Small-Colony Mutants of Staphylococcus aureus Allow Selection of Gyrase-Mediated Resistance to Dual-Target Fluoroquinolones. Antimicrob. Agents Chemother. 46: 2498-2506 [Abstract] [Full Text]  
  • Weigel, L. M., Anderson, G. J., Tenover, F. C. (2002). DNA Gyrase and Topoisomerase IV Mutations Associated with Fluoroquinolone Resistance in Proteus mirabilis. Antimicrob. Agents Chemother. 46: 2582-2587 [Abstract] [Full Text]  
  • Houssaye, S., Gutmann, L., Varon, E. (2002). Topoisomerase Mutations Associated with In Vitro Selection of Resistance to Moxifloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46: 2712-2715 [Abstract] [Full Text]  
  • Yague, G., Morris, J. E., Pan, X.-S., Gould, K. A., Fisher, L. M. (2002). Cleavable-Complex Formation by Wild-Type and Quinolone-Resistant Streptococcus pneumoniae Type II Topoisomerases Mediated by Gemifloxacin and Other Fluoroquinolones. Antimicrob. Agents Chemother. 46: 413-419 [Abstract] [Full Text]  
  • Morris, J. E., Pan, X.-S., Fisher, L. M. (2002). Grepafloxacin, a Dimethyl Derivative of Ciprofloxacin, Acts Preferentially through Gyrase in Streptococcus pneumoniae: Role of the C-5 Group in Target Specificity. Antimicrob. Agents Chemother. 46: 582-585 [Abstract] [Full Text]  
  • Reinhardt, A. K., Bebear, C. M., Kobisch, M., Kempf, I., Gautier-Bouchardon, A. V. (2002). Characterization of Mutations in DNA Gyrase and Topoisomerase IV Involved in Quinolone Resistance of Mycoplasma gallisepticum Mutants Obtained In Vitro. Antimicrob. Agents Chemother. 46: 590-593 [Abstract] [Full Text]  
  • Weigel, L. M., Anderson, G. J., Facklam, R. R., Tenover, F. C. (2001). Genetic Analyses of Mutations Contributing to Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 3517-3523 [Abstract] [Full Text]  
  • Takei, M., Fukuda, H., Kishii, R., Hosaka, M. (2001). Target Preference of 15 Quinolones against Staphylococcus aureus, Based on Antibacterial Activities and Target Inhibition. Antimicrob. Agents Chemother. 45: 3544-3547 [Abstract] [Full Text]  
  • Fass, R. J., Barnishan, J. (2001). Comparison of antimicrobial in vitro activities against Streptococcus pneumoniae independent of MIC susceptibility breakpoints using MIC frequency distribution curves, scattergrams and linear regression analyses. J Antimicrob Chemother 48: 609-615 [Abstract] [Full Text]  
  • Pan, X.-S., Yague, G., Fisher, L. M. (2001). Quinolone Resistance Mutations in Streptococcus pneumoniae GyrA and ParC Proteins: Mechanistic Insights into Quinolone Action from Enzymatic Analysis, Intracellular Levels, and Phenotypes of Wild-Type and Mutant Proteins. Antimicrob. Agents Chemother. 45: 3140-3147 [Abstract] [Full Text]  
  • Fluit, A. C., Visser, M. R., Schmitz, F.-J. (2001). Molecular Detection of Antimicrobial Resistance. Clin. Microbiol. Rev. 14: 836-871 [Abstract] [Full Text]  
  • Ince, D., Hooper, D. C. (2001). Mechanisms and Frequency of Resistance to Gatifloxacin in Comparison to AM-1121 and Ciprofloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 2755-2764 [Abstract] [Full Text]  
  • Hartman-Neumann, S., DenBleyker, K., Pelosi, L. A., Lawrence, L. E., Barrett, J. F., Dougherty, T. J. (2001). Selection and Genetic Characterization of Streptococcus pneumoniae Mutants Resistant to the Des-F(6) Quinolone BMS-284756. Antimicrob. Agents Chemother. 45: 2865-2870 [Abstract] [Full Text]  
  • Nagai, K., Davies, T. A., Dewasse, B. E., Jacobs, M. R., Appelbaum, P. C. (2001). Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. J Antimicrob Chemother 48: 365-374 [Abstract] [Full Text]  
  • Roychoudhury, S., Twinem, T. L., Makin, K. M., McIntosh, E. J., Ledoussal, B., Catrenich, C. E. (2001). Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae. J Antimicrob Chemother 48: 29-36 [Abstract] [Full Text]  
  • Millichap, J. J., Pestova, E., Siddiqui, F., Noskin, G. A., Peterson, L. R. (2001). Fluoroquinolone Resistance Is a Poor Surrogate Marker for Type II Topoisomerase Mutations in Clinical Isolates of Streptococcus pneumoniae. J. Clin. Microbiol. 39: 2719-2721 [Abstract] [Full Text]  
  • Fukuda, H., Kishii, R., Takei, M., Hosaka, M. (2001). Contributions of the 8-Methoxy Group of Gatifloxacin to Resistance Selectivity, Target Preference, and Antibacterial Activity against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 1649-1653 [Abstract] [Full Text]  
  • Roychoudhury, S., Catrenich, C. E., McIntosh, E. J., McKeever, H. D., Makin, K. M., Koenigs, P. M., Ledoussal, B. (2001). Quinolone Resistance in Staphylococci: Activities of New Nonfluorinated Quinolones against Molecular Targets in Whole Cells and Clinical Isolates. Antimicrob. Agents Chemother. 45: 1115-1120 [Abstract] [Full Text]  
  • Boos, M., Mayer, S., Fischer, A., Köhrer, K., Scheuring, S., Heisig, P., Verhoef, J., Fluit, A. C., Schmitz, F.-J. (2001). In Vitro Development of Resistance to Six Quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 938-942 [Abstract] [Full Text]  
  • Blondeau, J. M., Zhao, X., Hansen, G., Drlica, K. (2001). Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 433-438 [Abstract] [Full Text]  
  • Earnshaw, D. L., Pope, A. J. (2001). FlashPlate Scintillation Proximity Assays for Characterization and Screening of DNA Polymerase, Primase, and Helicase Activities. J Biomol Screen 6: 39-46 [Abstract]  
  • Ince, D., Hooper, D. C. (2000). Mechanisms and Frequency of Resistance to Premafloxacin in Staphylococcus aureus: Novel Mutations Suggest Novel Drug-Target Interactions. Antimicrob. Agents Chemother. 44: 3344-3350 [Abstract] [Full Text]  
  • Bast, D. J., Low, D. E., Duncan, C. L., Kilburn, L., Mandell, L. A., Davidson, R. J., de Azavedo, J. C. S. (2000). Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae: Contributions of Type II Topoisomerase Mutations and Efflux to Levels of Resistance. Antimicrob. Agents Chemother. 44: 3049-3054 [Abstract] [Full Text]  
  • Heaton, V. J., Ambler, J. E., Fisher, L. M. (2000). Potent Antipneumococcal Activity of Gemifloxacin Is Associated with Dual Targeting of Gyrase and Topoisomerase IV, an In Vivo Target Preference for Gyrase, and Enhanced Stabilization of Cleavable Complexes In Vitro. Antimicrob. Agents Chemother. 44: 3112-3117 [Abstract] [Full Text]  
  • Yan, S. S., Fox, M. L., Holland, S. M., Stock, F., Gill, V. J., Fedorko, D. P. (2000). Resistance to Multiple Fluoroquinolones in a Clinical Isolate of Streptococcus pyogenes: Identification of gyrA and parC and Specification of Point Mutations Associated with Resistance. Antimicrob. Agents Chemother. 44: 3196-3198 [Abstract] [Full Text]  
  • Jones, M. E., Staples, A. M., Critchley, I., Thornsberry, C., Heinze, P., Engler, H. D., Sahm, D. F. (2000). Benchmarking the In Vitro Activities of Moxifloxacin and Comparator Agents against Recent Respiratory Isolates from 377 Medical Centers throughout the United States. Antimicrob. Agents Chemother. 44: 2645-2652 [Abstract] [Full Text]  
  • Bébéar, C. M., Grau, O., Charron, A., Renaudin, H., Gruson, D., Bébéar, C. (2000). Cloning and Nucleotide Sequence of the DNA Gyrase (gyrA) Gene from Mycoplasma hominis and Characterization of Quinolone-Resistant Mutants Selected In Vitro with Trovafloxacin. Antimicrob. Agents Chemother. 44: 2719-2727 [Abstract] [Full Text]  
  • Nagai, K., Davies, T. A., Pankuch, G. A., Dewasse, B. E., Jacobs, M. R., Appelbaum, P. C. (2000). In Vitro Selection of Resistance to Clinafloxacin, Ciprofloxacin, and Trovafloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44: 2740-2746 [Abstract] [Full Text]  
  • Sahm, D. F., Peterson, D. E., Critchley, I. A., Thornsberry, C. (2000). Analysis of Ciprofloxacin Activity against Streptococcus pneumoniae after 10 Years of Use in the United States. Antimicrob. Agents Chemother. 44: 2521-2524 [Abstract] [Full Text]  
  • Fournier, B., Zhao, X., Lu, T., Drlica, K., Hooper, D. C. (2000). Selective Targeting of Topoisomerase IV and DNA Gyrase in Staphylococcus aureus: Different Patterns of Quinolone- Induced Inhibition of DNA Synthesis. Antimicrob. Agents Chemother. 44: 2160-2165 [Abstract] [Full Text]  
  • Guerin, F., Varon, E., Hoï, A. B., Gutmann, L., Podglajen, I. (2000). Fluoroquinolone Resistance Associated with Target Mutations and Active Efflux in Oropharyngeal Colonizing Isolates of Viridans Group Streptococci. Antimicrob. Agents Chemother. 44: 2197-2200 [Abstract] [Full Text]  
  • Thomson, K. S. (2000). Minimizing quinolone resistance: are the new agents more or less likely to cause resistance?. J Antimicrob Chemother 45: 719-723 [Full Text]  
  • Kaneko, A., Sasaki, J., Shimadzu, M., Kanayama, A., Saika, T., Kobayashi, I. (2000). Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci. J Antimicrob Chemother 45: 771-775 [Abstract] [Full Text]  
  • Alovero, F. L., Pan, X.-S., Morris, J. E., Manzo, R. H., Fisher, L. M. (2000). Engineering the Specificity of Antibacterial Fluoroquinolones: Benzenesulfonamide Modifications at C-7 of Ciprofloxacin Change Its Primary Target in Streptococcus pneumoniae from Topoisomerase IV to Gyrase. Antimicrob. Agents Chemother. 44: 320-325 [Abstract] [Full Text]  
  • Jones, M. E., Sahm, D. F., Martin, N., Scheuring, S., Heisig, P., Thornsberry, C., Köhrer, K., Schmitz, F.-J. (2000). Prevalence of gyrA, gyrB, parC, and parE Mutations in Clinical Isolates of Streptococcus pneumoniae with Decreased Susceptibilities to Different Fluoroquinolones and Originating from Worldwide Surveillance Studies during the 1997-1998 Respiratory Season. Antimicrob. Agents Chemother. 44: 462-466 [Abstract] [Full Text]  
  • Heaton, V. J., Goldsmith, C. E., Ambler, J. E., Fisher, L. M. (1999). Activity of Gemifloxacin against Penicillin- and Ciprofloxacin-Resistant Streptococcus pneumoniae Displaying Topoisomerase- and Efflux-Mediated Resistance Mechanisms. Antimicrob. Agents Chemother. 43: 2998-3000 [Abstract] [Full Text]  
  • Morrissey, I., George, J. (1999). Activities of Fluoroquinolones against Streptococcus pneumoniae Type II Topoisomerases Purified as Recombinant Proteins. Antimicrob. Agents Chemother. 43: 2579-2585 [Abstract] [Full Text]  
  • Earnshaw, D. L., Moore, K. J., Greenwood, C. J., Djaballah, H., Jurewicz, A. J., Murray, K. J., Pope, A. J. (1999). Time-Resolved Fluorescence Energy Transfer DNA Helicase Assays for High Throughput Screening. J Biomol Screen 4: 239-248 [Abstract]  
  • Kenny, G. E., Young, P. A., Cartwright, F. D., Sjöström, K. E., Huang, W. M. (1999). Ofloxacin Selects Gyrase Mutations in First-Step Mycoplasma hominis Mutants, whereas Sparfloxacin Selects Topoisomerase IV Mutations. Antimicrob. Agents Chemother. 43: 2493-2496 [Abstract] [Full Text]  
  • Brisse, S., Fluit, A. C., Wagner, U., Heisig, P., Milatovic, D., Verhoef, J., Scheuring, S., Köhrer, K., Schmitz, F.-J. (1999). Association of Alterations in ParC and GyrA Proteins with Resistance of Clinical Isolates of Enterococcus faecium to Nine Different Fluoroquinolones. Antimicrob. Agents Chemother. 43: 2513-2516 [Abstract] [Full Text]  
  • Pan, X.-S., Fisher, L. M. (1999). Streptococcus pneumoniae DNA Gyrase and Topoisomerase IV: Overexpression, Purification, and Differential Inhibition by Fluoroquinolones. Antimicrob. Agents Chemother. 43: 1129-1136 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»